Drugs · acquisition-cost intelligence
Escitalopram
escitalopram· ingredient escitalopramSelective serotonin reuptake inhibitors· ESCITALOPRAM OXALATE 10 mg/1; ESCITALOPRAM OXALATE 10 mg/21; ESCITALOPRAM OXALATE 20 mg/1; ESCITALOPRAM OXALATE 20 mg/21
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.04188
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 8 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other escitalopram products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Escitalopram | $0.04188 | +$0.00000 |
| Escitalopram | $0.15536 | +$0.11350 |
| escitalopram | $5.42 | +$5.38 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 34% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.